



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-269/S-001

Pfizer Inc.
Attention: Kathy Collins
Director, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Ms. Collins:

Please refer to your supplemental new drug application dated August 31, 2005, received September 1, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cardura® XL (doxazosin mesylate) extended release tablets.

We acknowledge receipt of your submission dated March 3, 2006, which constituted a complete response to our February 14, 2006, action letter.

This supplemental new drug application provides for labeling revisions concerning Intraoperative Floppy Iris Syndrome (IFIS).

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted March 3, 2006).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-269/S-001.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Martin Kaufman, D.P.M., M.B.A., Regulatory Health Project Manager, at (301) 796-0928.

Sincerely,

{See appended electronic signature page}

Daniel Shames, M.D., F.A.C.S.
Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Daniel A. Shames
3/24/2006 02:35:00 PM